ARID1B and neoplasm: A univariate analysis showed that FIGO stage III/IV (p < 0.0001, log-rank test), CA125 level (p = 0.0088, log-rank test), residual tumor diameter ≥2 cm (p < 0.0001, log-rank test), and low ARID1B expression (p = 0.04, log-rank test) were correlated with shorter progression-free survival (Table 3).